A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+/HER2-breast Cancer
Interventions: DRUG: Standard endocrine therapy plus Apatinib
Sponsor: Fudan University